Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 837.49M P/E - EPS this Y -2.00% Ern Qtrly Grth -
Income -180.66M Forward P/E -4.14 EPS next Y -6.60% 50D Avg Chg -8.00%
Sales 26.98M PEG - EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book 2.86 EPS next 5Y - 52W High Chg -31.00%
Recommedations 1.80 Quick Ratio 7.92 Shares Outstanding 37.97M 52W Low Chg 23.00%
Insider Own 6.17% ROA -23.60% Shares Float - Beta 0.89
Inst Own 91.75% ROE -56.31% Shares Shorted/Prior 2.54M/2.76M Price 23.16
Gross Margin - Profit Margin - Avg. Volume 202,477 Target Price 43.20
Oper. Margin -1,017.35% Earnings Date May 2 Volume 317,904 Change -5.35%
About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics plc News
04/02/24 Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03/05/24 Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
02/28/24 Bicycle Therapeutics to Participate in Upcoming Investor Conferences
02/23/24 Earnings Update: Bicycle Therapeutics plc (NASDAQ:BCYC) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
02/21/24 Bicycle Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
02/20/24 Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
02/07/24 Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/22/24 15 Small-Cap Stocks with High Potential
01/05/24 Bicycle Therapeutics PLC CEO Kevin Lee Sells 8,703 Shares
12/14/23 Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
11/30/23 Bicycle Therapeutics to Host R&D Day on December 14
11/07/23 Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Just Trimmed Their Revenue Forecasts By 13%
11/02/23 Bicycle Therapeutics PLC (BCYC) Reports Q3 2023 Financial Results and Upcoming R&D Day
11/02/23 Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
11/02/23 ‘The Stage Is Set for a Rally’: Canaccord Sees up to 290% Upside for These 3 Stocks
06:00 AM Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer
03:00 AM Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
10/07/23 An excellent week for Bicycle Therapeutics plc's (NASDAQ:BCYC) institutional owners who own 64% as one-year returns inch higher
09/14/23 Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
09/12/23 Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up
BCYC Chatroom

User Image SmartestMoney Posted - 17 hours ago

$BCYC Stayin’ alive

User Image IsabellaDC Posted - 21 hours ago

Something can be good here: Spitting out a scan. I haven't looked at them thoroughly. $BCYC $IRDM $APOG $B $GL and so on...

User Image BiotechJedi1728 Posted - 22 hours ago

$BCYC Nice.

User Image erevnon Posted - 1 week ago

Needham reiterates Bicycle Therapeutics $BCYC at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image BiotechJedi1728 Posted - 1 week ago

$BCYC I am in now.

User Image bigtuna7 Posted - 1 week ago

Inverse H&S setups all over bios $XBI $CRSP $FLGT $BCYC

User Image bigtuna7 Posted - 1 week ago

$FLGT $BCYC Took some

User Image Stock_Titan Posted - 2 weeks ago

$BCYC Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-to-participate-in-the-23rd-annual-needham-8i8s7hbrjx2t.html

User Image jones_ Posted - 03/20/24

$BCYC round 2 flagging measured move to $40. Stochs primed

User Image bigtuna7 Posted - 1 month ago

$BCYC that candle today tho ……..⬆️ ⬆️⬆️

User Image jones_ Posted - 1 month ago

$BCYC after hours pop

User Image Theflash88 Posted - 1 month ago

$BCYC Because I bought this morning.

User Image Stock_Titan Posted - 1 month ago

$BCYC Bicycle Therapeutics to Present at the AACR Annual Meeting 2024 https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-to-present-at-the-aacr-annual-meeting-6vyy9mvqg8xn.html

User Image 50bps Posted - 02/28/24

all i wanna do is $BCYC

User Image jones_ Posted - 02/28/24

$BCYC big open here

User Image Stock_Titan Posted - 02/28/24

$BCYC Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-to-participate-in-upcoming-investor-h4hn656wpl2y.html

User Image SmartestMoney Posted - 02/26/24

$BCYC 7🌲%

User Image Tommy_Two_Toes Posted - 02/21/24

$BCYC go

User Image kclan Posted - 02/21/24

$BCYC a slow march back to $45 would be appreciated. My thanks in advance! 😊

User Image jones_ Posted - 02/21/24

$BCYC Easy W

User Image erevnon Posted - 02/21/24

Needham reiterates Bicycle Therapeutics $BCYC at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image SmartestMoney Posted - 02/20/24

$BCYC Yes 🚲

User Image DonCorleone77 Posted - 02/20/24

$BCYC Bicycle Therapeutics reports Q4 EPS ($1.16), consensus ($1.23) Cash and cash equivalents were $526.4M as of December 31, 2023, compared to $339.2M as of December 31, 2022. "2023 was a pivotal year for our company, during which we achieved significant progress across our Nectin-4 and EphA2 clinical oncology portfolios and our discovery pipeline of next-generation Bicycle(R) molecules, including in radiopharmaceuticals and areas beyond oncology. We continue to demonstrate our ability to develop highly differentiated, precision-guided therapeutics that may offer greater tolerability and lead to enhanced benefit for patients," said Kevin Lee, CEO of Bicycle Therapeutics. "With a catalyst-rich 2024 expected, a strong financial position, validating partnerships and a unique platform technology, we enter this year with significant momentum and focus to advance our mission to help patients not only live longer but also live well."

User Image epsguid Posted - 02/20/24

$BCYC reported a loss of $1.16, consensus was ($1.23) via @eWhispers #epsbeat http://eps.sh/d/bcyc

User Image Stock_Titan Posted - 02/20/24

$BCYC $CYTT Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-reports-recent-business-progress-and-fourth-i42zfnsus6so.html

User Image jones_ Posted - 2 months ago

$BCYC solid weekly close, bucking the trend

User Image MMCT Posted - 2 months ago

$ATHA Bakers Bros bought a stake here like $BCYC 🤔

User Image MMCT Posted - 2 months ago

$BCYC $GERN $MDGL $SSRM Thanks to all bulls 🥰

User Image MMCT Posted - 2 months ago

@watrconservation well be careful my friend. Some of my posts got a different strategy. Like $GERN i am annoyed that this was like at 1.85/1.9 $ for some time and it went up like 2.4 and it hit my first target. So i already had some profits and i hold some for adcom in march. Same goes for $MDGL bought really much for priority review pdufa added between 170 to 188$ and sold half at 213$ and holding some for march pdufa as well. $SSRM is quite different. It got high risk and high volality. Goes on heavily bad news and i only went on bounce and have small for watchlist. Some others like $BCYC i only buy because of Baker Brothers bought it and also sold 2/3 at the end of the day.

User Image Stocksrunner Posted - 2 months ago

🚀 Greetings Traders! 🚀 Exciting news for those betting on $BCYC and $JBLU! 🚴‍♂️ $BCYC: Bicycle Therapeutics gains momentum with a boost in stake, signaling positive growth. ✈️ $JBLU: JetBlue soars as Carl Icahn discloses a 9.91% stake, driving shares up 16%. 📈 Board talks in progress, and Icahn calls shares undervalued. Stay tuned for potential market shifts! https://stocksrunner.com/home

Analyst Ratings
Needham Buy Apr 10, 24
Canaccord Genuity Buy Feb 21, 24
HC Wainwright & Co. Buy Feb 21, 24
Needham Buy Feb 21, 24
JMP Securities Market Outperform Dec 20, 23
Needham Buy Dec 15, 23
Cantor Fitzgerald Overweight Nov 8, 23
Morgan Stanley Equal-Weight Nov 3, 23
B. Riley Securities Buy Sep 12, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Thompson Travis Alvin Chief Accounting Off.. Chief Accounting Officer Jan 02 Sell 17.5 604 10,570 23,375 01/04/24
Keen Nicholas Chief Scientific Off.. Chief Scientific Officer Jan 02 Sell 17.5 2,640 46,200 63,593 01/04/24
Crockett Nigel Chief Business Offic.. Chief Business Officer Jan 02 Sell 17.5 2,643 46,252 48,716 01/04/24
Milnes Alistair Chief Operating Offi.. Chief Operating Officer Jan 02 Sell 17.5 2,643 46,252 73,196 01/04/24
Skynner Michael Chief Technology Off.. Chief Technology Officer Jan 02 Sell 17.5 2,643 46,252 95,839 01/04/24
Lee Kevin Chief Executive Offi.. Chief Executive Officer Jan 02 Sell 17.5 8,703 152,302 390,428 01/04/24
Thompson Travis Alvin Chief Accounting Off.. Chief Accounting Officer Oct 03 Sell 20.00 54 1,080 7,979 10/05/23
Keen Nicholas Chief Scientific Off.. Chief Scientific Officer Oct 03 Sell 20.00 272 5,440 38,233 10/05/23
Crockett Nigel Chief Business Offic.. Chief Business Officer Oct 03 Sell 20.00 442 8,840 29,359 10/05/23
Milnes Alistair Chief Operating Offi.. Chief Operating Officer Oct 03 Sell 20.00 442 8,840 36,839 10/05/23
Lee Kevin Chief Executive Offi.. Chief Executive Officer Oct 03 Sell 20.00 1,470 29,400 322,131 10/05/23
Skynner Michael Chief Technology Off.. Chief Technology Officer Oct 03 Sell 20.00 442 8,840 70,482 10/05/23
Thompson Travis Alvin Chief Accounting Off.. Chief Accounting Officer Jul 03 Sell 25.10 61 1,531 8,033 07/06/23
Skynner Michael Chief Technology Off.. Chief Technology Officer Jul 03 Sell 25.10 451 11,320 70,924 07/06/23
Milnes Alistair Chief Operating Offi.. Chief Operating Officer Jul 03 Sell 25.10 451 11,320 37,281 07/06/23
Lee Kevin Chief Executive Offi.. Chief Executive Officer Jul 03 Sell 25.10 1,498 37,600 323,601 07/06/23
Keen Nicholas Chief Scientific Off.. Chief Scientific Officer Jul 03 Sell 25.10 336 8,434 38,505 07/06/23
Crockett Nigel Chief Business Offic.. Chief Business Officer Jul 03 Sell 25.10 451 11,320 29,801 07/06/23
Crockett Nigel Chief Business Offic.. Chief Business Officer Jan 03 Sell 29.06 1,801 52,337 30,699 01/05/23
Milnes Alistair Chief Operating Offi.. Chief Operating Officer Jan 03 Sell 29.06 1,801 52,337 38,179 01/05/23
Smethurst Dominic Chief Medical Office.. Chief Medical Officer Jan 03 Sell 29.06 1,801 52,337 36,699 01/05/23
Skynner Michael Chief Technology Off.. Chief Technology Officer Jan 03 Sell 29.06 1,801 52,337 71,822 01/05/23
Keen Nicholas Chief Scientific Off.. Chief Scientific Officer Jan 03 Sell 29.06 1,817 52,802 39,160 01/05/23
Kalowski Lee President and CFO President and CFO Jan 03 Sell 29.06 1,815 52,744 30,685 01/05/23
Lee Kevin Chief Executive Offi.. Chief Executive Officer Jan 03 Sell 29.06 6,000 174,360 326,585 01/05/23
Legault Pierre Director Director Dec 20 Option 8.44 150,000 1,266,000 97,860 12/22/21
Legault Pierre Director Director Dec 20 Sell 57.38 150,000 8,607,000 12/22/21
Lee Kevin Chief Executive Offi.. Chief Executive Officer Oct 14 Sell 60.02 5,000 300,100 225,085 10/18/21
Lee Kevin Chief Executive Offi.. Chief Executive Officer Oct 11 Sell 54.22 5,000 271,100 230,085 10/13/21
Kalowski Lee President and CFO President and CFO Sep 03 Sell 40 10,000 400,000 09/03/21
Kalowski Lee President and CFO President and CFO Sep 03 Option 9.82 10,000 98,200 10,000 09/03/21